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Abstract 
Nicotine underlies the reinforcing properties of tobacco cigarettes and e-cigarettes. After 
inhalation and absorption, nicotine binds to various nicotinic acetylcholine receptor (nAChR) 
subtypes localized on the pre- and post-synaptic membranes of cells, which subsequently leads 
to the modulation of cellular function and neurotransmitter signaling. In this chapter, we begin 
by briefly reviewing the current understanding of nicotine’s actions on nAChRs and highlight 
considerations regarding nAChR subtype localization and pharmacodynamics. Thereafter, we 
discuss the seminal discoveries derived from genetically modified mouse models, which have 
greatly contributed to our understanding of nicotine’s effects on the reward-related mesolimbic 
pathway and the aversion-related habenulo-interpeduncular pathway. Thereafter, emerging 
areas of research focusing on modulation of nAChR expression and/or function are considered. 
Taken together, these discoveries have provided a foundational understanding of various 
genetic, neurobiological and behavioral factors underlying the motivation to use nicotine and 
related dependence processes, which are thereby advancing drug discovery efforts to promote 
long-term abstinence. 
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Introduction 
Nicotine is the primary active constituent in tobacco-containing products, which is responsible 
for maintaining smoking behavior in humans (Stolerman and Jarvis 1995).  Recently, nicotine has 
also been formulated for vapor inhalation via e-cigarettes devices (Electronic Nicotine Delivery 
Systems, or ENDS; (St Helen et al. 2016)). Concomitant with a decrease in combustible tobacco 
cigarette use, use of e-cigarettes, especially among adolescents, has drastically risen in recent 
years (Wang et al. 2018). Indeed, from 2017-2018, there was a rapid increase in vaping 
prevalence among adolescents aged ~13-18 years old, with nicotine vaping rates translating to 
roughly an additional 1.3 million adolescent users in 2018 compared to 2017 (Miech et al. 2019). 
Although e-cigarettes may have value as a nicotine replacement strategy for current tobacco 
smokers (Hajek et al. 2019), the increasing patterns of e-cigarette use among adolescents has 
become of high concern and warrants further investigation. As well, among current smokers, 
some studies show that e-cigarettes are not liked as much as tobacco cigarettes (Strasser et al. 
2016), and therefore, additional research is needed to determine the ability of e-cigarettes to 
accomplish nicotine replacement, harm reduction, or act as a quit aid (Rennie et al. 2016; Selya 
et al. 2018).  
 
Chronic exposure to nicotine or nicotine-containing products is associated with detrimental 
health effects, including enhanced brain injury and/or stroke risk (Sifat et al. 2018), altered blood 
brain barrier permeability (Hawkins et al. 2004), promotion of tumor growth via nicotine and its 
carcinogenic metabolites cotinine, Nʹ-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK; (Ginzkey et al. 2013; Ginzkey et al. 2012; Jacob et al. 2009; Nakada et 
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al. 2012), early onset of menopause in women (Bellavia et al. 2016), among others. Of 
importance, recent research has found that e-cigarette smoke may be carcinogenic and lead to 
increased risk of lung and bladder cancer, as well as heart disease, due to DNA damage (Lee et 
al. 2018). Given the harmful health effects associated with chronic use of nicotine-containing 
products, understanding the mechanisms that drive nicotine use is essential. 
 
Nicotine is an agonist at nicotinic acetylcholine receptors (nAChRs), the structure and function of 
which were discovered in the early 1980s using ligand-binding assays (Clarke et al. 1985; Patrick 
and Stallcup 1977). The nAChRs are members of a large family of cys-loop homologous receptors, 
which also includes muscle acetylcholine receptors (mAChRs), GABAA/C, glycine, and serotonin 
type 3 receptors (Miller and Smart 2010). The nAChRs are pentameric ion channels, whereby 
either homomeric or heteromeric subunits combine together to form a central pore (Zoli et al. 
2015). The subunit composition and stoichiometry of nAChRs determine its unique 
pharmacological binding profile, as well as its susceptibility to desensitization (Picciotto et al. 
2008).   
 
Decades of research has uncovered important neural mechanisms that drive nicotine self-
administration behavior. Specifically, nicotine engenders self-administration through activation 
of high affinity β2 subunit-containing (denoted b2*) nAChRs localized on dopamine-containing 
cell bodies within the ventral tegmental area (VTA; (Klink et al. 2001; Picciotto et al. 1998)), and 
by altering glutamatergic and GABAergic tone in the VTA (Mansvelder et al. 2002). The net result 
of nicotine-induced activation of nAChRs is increased levels of extracellular dopamine within the 
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nucleus accumbens (NAc; (Pontieri et al. 1996)), which is hypothesized to contribute to its 
reinforcing effects. Although activation of nAChRs can lead to motivated behavior, it is also 
through desensitization/inactivation that nAChRs can alter acetylcholine signaling and neuronal 
function (Colombo et al. 2013), which may also contribute to modulation of nicotine-motivated 
behavior. Importantly, both acetylcholine and nicotine lead to nAChR desensitization; however, 
nicotine leads to prolonged inactivation of these receptors, with a slower rate of recovery than 
the endogenous ligand (Giniatullin et al. 2005). Interestingly, ɑ4β2 nAChR desensitization occurs 
following cigarette smoking, which is correlated with reductions in cigarette craving (Brody et al. 
2006). 
 
It is important to note that nAChRs are expressed neuronally, on both pre- and post-synaptic 
terminals as well as on post-synaptic somatodendrites (Albuquerque et al. 2009). Additionally, 
some nAChRs (e.g., homomeric ɑ7) are localized on astrocytes and microglia in the brain (Graham 
et al. 2003; Jensen et al. 1997; Noda and Kobayashi 2017; Shen and Yakel 2012; Shytle et al. 
2004), which have important functions at glutamatergic neuronal synapses that impact synaptic 
plasticity (Wang et al. 2013). Subunit composition of nAChRs in the brain can vary depending on 
region and cell-type specific localization, the topography of which continues to be studied 
(Gaimarri et al. 2007; Gotti et al. 2006; Hendrickson et al. 2013), and is important in 
understanding neurobehavioral processes modulated by nAChRs.  
 
In this chapter, we describe the current state of the knowledge regarding nAChR subtype 
expression in a brain region- and pathway-specific manner as it relates to nicotine dependence 
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and comorbid pathologies. To accomplish this goal, we address current tools in the field that have 
allowed for exploration of the role of nAChR function and expression in addiction-related 
processes, with a focus on findings garnered from transgenic mouse models. As well, we 
illuminate novel areas of research focusing on modulating nAChR expression and/or function, 
which may have important implications for nicotine dependence processes. Given the evolving 
landscape of nicotine-containing product use (Fowler et al. 2017), a better understanding of the 
neural processes underlying the motivation to use nicotine is needed to enhance drug discovery 
efforts to promote cessation from nicotine-containing products. 
 
nAChR Function and Signaling 
As noted above, the nAChR receptor composition plays an important role in response to 
pharmacological agents. When an agonist (e.g., acetylcholine or nicotine) is bound to nAChRs, 
the receptors are first activated and then can desensitize, followed by recovery once the agonist 
is unbound. The EC50 value, which represents nAChR activation for the concentration of agonist 
producing half-maximal response amplitude, varies based on subunit composition. For example, 
the acetylcholine EC50 value is 513 for rat ɑ7 (Papke and Porter Papke 2002), but is 14 for rat 
ɑ3β4 (Bohler et al. 2001). Conversely, the measure for desensitization, or the concentration of 
agonist required to reduce the amplitude of the response by 50%, is termed the IC50. Based on 
subunit composition, desensitization-induced inhibition of receptors can vary when activated by 
the same agonist; for instance, the rat ɑ4β2 IC50 with nicotine is <0.01 (Paradiso and Steinbach 
2003), whereas rat ɑ7 is 1.3 (Fenster et al. 1997; Giniatullin et al. 2005). These values represent 
different rates of activation and inhibition, which have profound effects on nAChR modulation of 
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neuronal function. It should be noted that the same receptor subtype can desensitize at different 
rates based on the agonist present. For example, rat ɑ7 IC50 value is 1.3 for nicotine, but is 
>10,000 for acetylcholine (Fenster et al. 1997; Papke and Porter Papke 2002). This is important 
because recovery rates are dependent upon the agonist present, with recovery rate from nicotine 
taking longer than acetylcholine in some cases (e.g., ɑ4β2; (Paradiso and Steinbach 2003)). Given 
the important role of nAChR subtypes such as ɑ4β2 in the reinforcing effects of nicotine 
(Changeux et al. 1998) and in modulating dopamine release (Mansvelder and McGehee 2002), 
different rates of desensitization and recovery of different nAChRs likely play key roles in the 
neural circuitry underlying nicotine addiction. 
 
There are generally two binding sites for neuronal heteromeric nAChRs, each of which is formed 
by a pocket between subunits extracellularly at the ligand-binding N-terminal domain (Karlin 
2002; Sine et al. 2002). Neuronally, ɑ7 nAChRs are mainly homomeric and have five potential 
binding sites between the ɑ subunits (Drisdel and Green 2000). Recently, additional binding sites 
for heteromeric nAChRs have been identified which are dependent on subunit composition (Jain 
et al. 2016). When a ligand is bound, the channel opens within microseconds (Albuquerque et al. 
2009), indicative of the rapid responsivity of these channels. A sequence of events occurs to alter 
the conformational state of the channel in order to open. Through computer generated 
modeling, it has been determined that when acetylcholine or nicotine is bound, hydrogen bonds 
among amino acids rearrange near the binding pocket. Subsequently, the C-loop moves toward 
the central pore, which then allows the Cys-Cys pair to interact with the bound ligand and results 
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in the ligand being trapped deep within the pore between the subunits (Gao et al. 2005; Hansen 
et al. 2005).   
 
As mentioned above, neuronal nAChRs can be expressed somatodendritically, pre-synaptically, 
or post-synaptically (Broide and Leslie 1999; McGehee et al. 1995; Wonnacott 1997). Nicotine 
binds to nAChRs located in the brain, which have identified subunits of α2-7, and β2-4 (Boulter 
et al. 1987; Couturier et al. 1990; Picciotto et al. 2008). Somatodendritically-expressed nAChRs 
play a modulatory role in the neurotransmission of other systems in response to nicotine 
(Wonnacott et al. 2006), such as dopamine (Nisell et al. 1994). nAChRs that are expressed 
somatodendritically and modulate dopamine release appear to contain α6 and β3 subunits, and 
differ in pharmacological response to nicotine and epibatidine compared to those expressed on 
terminals in the striatum (Reuben et al. 2000). Presynaptic nAChRs are also important in 
modulating neurotransmitter release. For instance, α7 nAChRs are Ca2+-permeable, rapidly 
desensitize following activation and are expressed on many cell types including at glutamatergic 
terminals in brain regions such as the hippocampus and NAc (Fabian-Fine et al. 2001; Kaiser and 
Wonnacott 2000). Thus, nAChRs can enhance release of neurotransmitters from synaptic 
terminals, and may provide a feedforward mechanism by which cholinergic signaling gates 
neurotransmitter release. Post-synaptically, nAChRs modulate many functions within the brain, 
including the flow of auditory information in the thalamus. Specifically, β2-containing 
heteromeric nAChRs are located on neurons within the medial geniculate body receive 
cholinergic input from the pontomesencephalic tegmentum, and these receptors undergo an 
age-related decline in their expression and function (Sottile et al. 2017). As well, postsynaptic 
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nAChR subunits such as α6, α7, β2, and/or β4 within the laterodorsal tegmentum, undergo 
changes in subunit composition due to age, which results in differential nicotine-induced 
neuronal excitability (Christensen and Kohlmeier 2016; Kaneda 2017; Kaneda et al. 2016; 
Shinohara et al. 2014; Taoka et al. 2016).  
 
For decades, research has shown that chronic exposure to nicotine significantly alters expression 
and function of neuronal nAChRs (Fenster et al. 1999a; Fenster et al. 1999b; Gentry and Lukas 
2002; Quick and Lester 2002). One nAChR subunit heavily involved in nicotine-induced striatal 
dopamine release and nicotine self-administration behavior, β2 (see a more thorough description 
below), is upregulated and desensitized after chronic nicotine exposure, as measured via binding 
assays in intact oocytes (Fenster et al. 1999b). Following chronic activation due to nicotine, 
different subunit-containing nAChRs appear to desensitize at different rates, which is thought to 
underlie their ability to modulate different neurotransmitter systems. Further, changes in 
receptor expression with chronic nicotine appears to be cell type and nAChR subtype dependent 
(Benwell et al. 1988; Lallai et al. 2019; Marks et al. 1992; Perry et al. 1999). Both neuronal and 
non-neuronal cholinergic signaling involves some of the same subtypes of nAChRs and are 
associated with pathologies such as lung cancer (Mucchietto et al. 2016). One such subunit is ɑ5, 
which is expressed in non-neuronal tissues (Chini et al. 1992) such as lung, pancreas, stomach, 
and gliomas (Jia et al. 2016; Yoshikawa et al. 2005; Zia et al. 1997), and may mediate nicotine-
induced lung cancer cell proliferation (Ma et al. 2014; Sun and Ma 2015). This subunit forms 
functional complexes with ɑ4β2 or ɑ3β4 subunits, and polymorphism of the human a5 gene, 
CHRNA5, is associated with nicotine dependence and lung cancer (Bierut et al. 2008; Chen et al. 
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2009; Saccone et al. 2009; Saccone et al. 2007). Importantly, the variant of ɑ5, characterized by 
a change in the 398th amino acid from aspartic acid to asparagine (D398N), has been associated 
with a reduction in the function of the human α3β4α5 nAChR (George et al. 2012), which has 
important implications for smoking cessation outcomes as well as other health pathologies. 
 
nAChRs Mediating Nicotine Reinforcement 
Genetically modified mouse models have allowed for the interrogation of receptors and circuits 
underlying complex behaviors. In the tobacco and nicotine field, groundbreaking studies by 
Picciotto, Changeux and colleagues (Picciotto et al. 1995; Picciotto et al. 1998) have provided an 
important foundation for the further progression of these animal models. Beginning with 
knockout mice, subsequent approaches have incorporated various genetic and technical tools to 
achieve more select manipulation of target protein or neurotransmitter function. These advances 
include, but are not limited to, humanized knockin genes, modified receptors, cre driver lines 
with floxed viral approaches, optogenetic and chemicogenetic expression of receptors in a cell 
type specific manner, promotor driven fluorescent reporter lines, and most recently, CRISPR-
Cas9 directed genetic modifications. Findings derived thus far from such approaches within each 
circuit are discussed in the following paragraphs. 
 
Mesolimbic Pathway 
The positive rewarding effects of nicotine involve the brain’s mesolimbic pathway (Kenny and 
Markou 2005; Rice and Cragg 2004), consisting of dopaminergic projections from the VTA. The 
VTA integrating circuits and projection regions contain various nAChR subtypes expressed on 
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dopaminergic, glutamatergic and GABAergic neurons (Charpantier et al. 1998; Klink et al. 2001; 
Mameli-Engvall et al. 2006; Mansvelder and McGehee 2002). For instance, inhibitory GABAergic 
projections from the rostromedial tegmental nucleus (RMTg) express terminal a4b2* nAChRs. 
VTA dopaminergic cells projecting to both the NAc and prefrontal cortex (PFC) express a4a6b2, 
a4b2, and a6b2 nAChRs, allowing for regulation of dopamine signaling through either somatic 
or presynaptic expression. These VTA dopaminergic neurons may also co-express glutamate or 
GABA, and it has been recently shown that heteromeric nAChRs mediate excitatory signaling in 
the dopaminergic-glutamate co-expressing cells (Yan et al. 2018). Within the NAc, the 
dopaminergic terminal nAChRs become activated by cholinergic interneurons and modulate 
dopamine’s activation of GABAergic medium spiny neurons expressing dopamine D1 or D2 
receptors. Intra-VTA glutamatergic circuits also appear to modulate GABAergic signaling via 
axoaxonic connections onto RMTg terminals. Further, glutamatergic projections from other brain 
regions, such as the PFC and subiculum, express presynaptic a7 nAChRs and have been found to 
terminate on the soma of dopaminergic neurons. Moreover, expression of the a2, a5 and b3 
nAChR subunits have also been localized within the VTA. Together, this complicated pattern of 
nAChR expression makes defining the specific subtype contribution to nicotine reward and 
reinforcement challenging. However, significant advances have been made in this regard.  
 
Initial studies in knockout mice have supported pharmacological findings implicating nAChRs 
expressing the b2 nAChR subunit in mediating reward- and reinforcement-related processes. In 
the striatum, nicotine application induces a robust increase in dopamine release, which can be 
blocked by administration of the nAChR antagonist mecamylamine (Mifsud et al. 1989). However, 
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this nicotine-mediated increase in dopamine release was absent in the striatum of mice lacking 
the b2 nAChR subunit (Picciotto et al. 1998). To examine the involvement of this subunit on 
nicotine reinforcement, mice were assessed in an intravenous nicotine self-administration 
protocol, a technique with high translational validity to patterns of nicotine consumption in 
humans. Interestingly, while the wildtype mice exhibited sustained nicotine self-administration 
behavior, the b2 knockout mice did not self-administer nicotine (Picciotto et al. 1998). A further 
study revealed similar findings with a lack of sustained self-administration behavior in the 
absence of the b2 nAChR subunit with nicotine infusions directly into the VTA (Maskos et al. 
2005). More recently, viral mediated re-expression of the b2 nAChR subunit in the VTA of the 
knockout mice was shown to ‘rescue’ the behavioral phenotype, in which this site-specific re-
expression led to the mice acquiring nicotine self-administration (Orejarena et al. 2012). 
Additional support from studies with b2 knockout mice demonstrate that the b2* nAChR is 
necessary for the formation of a conditioned place preference to a nicotine-paired environment 
and the discriminative stimulus properties of nicotine (Shoaib et al. 2002; Walters et al. 2006). In 
a cutting edge approach, Mourot and colleagues used a viral technique to express light-
controllable b2* nAChRs in the VTA, and during light exposure, the VTA b2* nAChRs became 
inhibited, which thereby was sufficient to prevent the formation of a nicotine-induced 
conditioned place preference (Durand-de Cuttoli et al. 2018).  
 
In addition to the b2 subunit, lack of sustained nicotine self-administration has also been found 
in mice with knockout of the a4 and a6 nAChR subunits, and importantly, the behavioral 
phenotype could be restored with reexpression of these subunits in the VTA of each respective 
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knockout line (Exley et al. 2011; Maskos et al. 2005; Picciotto et al. 1998; Pons et al. 2008). 
Further, dopaminergic neuron specific deletion of the a4 subunit was found to prevent the 
formation of a nicotine-mediated conditioned place preference (McGranahan et al. 2011). In a 
complementary approach, transgenic a4 and a6 nAChR hypersensitive knockin mice were 
generated, in which a single point mutation renders the receptor subtype more responsive to 
nicotine. For the a4 subunit, this genetic modification led to an enhancement of the rewarding 
effects of nicotine, as assessed with conditioned place preference (Tapper et al. 2004), and for 
the a6 subunit, mice exhibited a potentiation of nicotine-mediated locomotor effects and 
increased glutamatergic transmission with VTA neurons (Berry et al. 2015).  As further evidence 
for these specific receptor subtypes, pharmacological administration of the relatively selective 
a4b2 nAChR antagonist, DHbE, also decreased nicotine self-administration in rats (Corrigall and 
Coen 1989; Harvey et al. 1996; Watkins et al. 1999). These findings are paralleled by studies 
demonstrating that DHbE attenuates the stimulatory effects of nicotine on brain reward systems 
(Harrison et al. 2002). Together, these findings support the notion that a4b2 and/or a4a6b2 
nAChRs on dopaminergic circuits in the VTA mediate the reinforcing properties of nicotine.  
 
The involvement of the a7 nAChR in nicotine dependence has been somewhat controversial. As 
noted above, glutamatergic axons containing presynaptic a7 nAChRs terminate on the soma of 
dopaminergic neurons in the VTA, suggesting a regulatory role for downstream dopaminergic 
signaling. Initial pharmacological studies demonstrated that administration of the a7 selective 
antagonist, methyllycaconitine, attenuates nicotine self-administration in rats (Markou and 
Paterson 2001), a finding that was further substantiated with site-specific VTA injections in 
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wildtype mice (Besson et al. 2012). However, studies in a7 nAChR knockout mice failed to find 
differences with intravenous nicotine self-administration and nicotine-mediated conditioned 
place preference compared to wildtype littermates (Pons et al. 2008). However, more recently, 
Granon and colleagues (2012) were able to establish a dose-dependent effect with intra-VTA 
nicotine self-administration, in which the a7 nAChR knockout mice exhibited decreased self-
administration at a low, but not high, nicotine dose. Further, when administered a peripheral 
injection of nicotine, nicotine-induced dopamine outflow in the NAc was sustained over a longer 
period of time in the a7 knockout mice (120 min), as compared to the wildtype mice (15 min) 
(Besson et al. 2012). In consideration of a7 nAChRs’ presynaptic circuit localization, lower affinity 
for nicotine, and rapid recovery from desensitization, the receptor’s effects on the mechanisms 
underlying nicotine reinforcement appear to be more nuanced.   
 
Habenulo-Interpeduncular Pathway 
As a drug of abuse, nicotine is distinctive in that the aversive properties appear to sharply 
contrast the rewarding properties of the drug, thereby limiting the range of doses that promote 
reinforcement and drug consumption.  Nicotine’s aversive effects are mediated by the medial 
habenula (MHb), a brain structure that directly projects to the interpeduncular nucleus (IPN). The 
MHb-IPN circuit has been characterized as containing the densest expression of cholinergic fibers 
and various nAChR subunits within the brain, including the a5, a3 and b4 nAChR subunits (Marks 
et al. 1992; Villani et al. 1983). The aversive signaling of this circuit has been demonstrated in 
several studies with genetically modified rodents. For instance, a5 nAChR subunit knockout mice 
exhibit a high level of motivation to consume large quantities of nicotine, and viral mediated re-
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expression of a5 subunits within this pathway restores nicotine intake to wildtype levels (Fowler 
et al. 2011). In addition, while wildtype mice exhibit inhibitory motivational effects at high doses 
of nicotine, the a5 nAChR knockout mice continue to exhibit reward-related effects, as assessed 
with both conditioned place preference and intracranial self-stimulation (Fowler et al. 2013; 
Jackson et al. 2010). The conclusions drawn from the knockout mice are supported by 
complementary studies using viral mediated knockdown of the a5 nAChR subunit in rats, in which 
decreased expression of a5 nAChR subunits selectively in the habenula similarly increase nicotine 
intake and also decreased the inhibitory effects of higher nicotine doses on the activity of the 
brain reward circuitry (Fowler et al. 2011). Presynaptic a5* nAChRs on MHb terminals appear to 
facilitate glutamate release from cholinergic and glutamatergic coexpressing axons in the IPN 
(Fowler et al. 2011; Girod and Role 2001), which is thought to mediate this effect. Further, chronic 
nicotine appears to mitigate the activation of a subpopulation of a5-expressing neurons in the 
IPN, which subsequently provide negative feedback onto habenular terminals and mitigate 
nicotine reward, as assessed with conditioned place preference (Ables et al. 2017). The presence 
of the α5 nAChR subunit in α4β2, α3β2 and α3β4 nAChR receptors have been shown to alter 
nicotine binding and/or desensitization kinetics in vitro (Ramirez-Latorre et al. 1996; Wang et al. 
1996), and all of these subtypes are expressed in the MHb-IPN pathway. Furthermore, the b4 
nAChR subunit has also been shown to mediate aversive processing for nicotine. Under 
conditions of  b4 nAChR subunit over-expression, mice consume less nicotine solution (Frahm et 
al. 2011), thereby suggesting that an a5b4* nAChR subtype may underlie an inhibitory 
motivational signal for nicotine in the MHb-IPN pathway. These findings in mouse models are 
further supported by human genome wide association studies demonstrating that allelic 
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variation in the CHRNA3-CHRNA5-CHRNB4 gene cluster, which encodes a3, a5 and b4, 
respectively, increases vulnerability to developing tobacco dependence (Bierut et al. 2008; 
Kapoor et al. 2012; Wang et al. 2009). Recently, the non-synonymous SNP in the a5 gene that 
has been implicated in nicotine dependence in humans was inserted into the genome of rats to 
generate a transgenic humanized a5SNP model (Forget et al. 2018). The behavior of the a5SNP 
rat closely parallels the mouse knockout model, in which greater levels of nicotine are self-
administered at high doses. In addition, an increase in nicotine-induced reinstatement was found 
in the a5SNP rats (Forget et al. 2018), suggesting a role for this genetic variant in relapse-related 
behavior.  
 
nAChRs in Other Aspects of Nicotine Dependence 
Nicotine Enhancement of Cue Association 
Nicotine administration has been shown to enhance the acquisition of certain learned behaviors, 
such as contextual fear conditioning and trace cued fear conditioning. These findings may 
underlie nicotine’s cue-related conditioning effects with drug use, in that later exposure to the 
cue during abstinence may promote drug relapse. Nicotine’s enhancing effect on contextual fear 
conditioning is prevented in mice with knockout of the b2, but not a7, nAChR subunit (Davis and 
Gould 2007; Portugal et al. 2008). These effects likely involve the hippocampus since systemic or 
site-specific hippocampal administration of the b2 nAChR antagonist DHbE mitigates contextual 
fear learning in wildtype, but not b2 subunit knockout, mice (Davis and Gould 2007; Portugal et 
al. 2008). An enhancement of nicotine-mediated cued, but not trace or contextual, fear 
conditioning was also found in female, but not male, a2 nAChR subunit knockout mice (Lotfipour 
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et al. 2013).  Interestingly, mice with a hypersensitive a2* nAChR exhibit impaired contextual 
fear conditioning, an effect which could be rescued with pretreatment of nicotine (Lotfipour et 
al. 2017).  
 
Nicotine Withdrawal 
Following chronic nicotine administration, wildtype mice exhibit a range of behaviors indicative 
of the withdrawal state, including somatic signs (such as shaking, paw tremors, writhing), 
increased anxiety-like behavior in the elevated plus maze, increased brain reward thresholds, 
learning deficits in a contextual fear conditioning paradigm, and development of a conditioned 
place aversion to a withdrawal-associated environment. Studies with the b2 knockout mouse 
indicate that b2* nAChRs are involved in withdrawal-related anxiety-like behavior and 
conditioned place aversion, but not in the expression of somatic withdrawal signs (Jackson et al. 
2008; Salas et al. 2004).  Further, a7 nAChRs have been implicated the initial expression of 
withdrawal symptomology, including anhedonia and somatic signs, but the a7 subunit knockout 
mice do not differ from wildtype mice at later time points (e.g., 24+ hours) (Grabus et al. 2005; 
Salas et al. 2007; Stoker et al. 2012). Moreover, decreased somatic withdrawal signs have been 
found in a2, a5 and b4 nAChR subunit knockout mice, as compared to their respective wildtype 
littermates (Lotfipour et al. 2013; Salas et al. 2004; Salas et al. 2009). Interestingly, all of these 
subunits exhibit selectively dense expression in the MHb-IPN pathway, which has also been 
specifically implicated in somatic aspects of nicotine withdrawal. Administration of the general 
nAChR antagonist mecamylamine into the MHb-IPN pathway is sufficient to precipitate 
withdrawal, whereas injections into the cortex, VTA or hippocampus are ineffective (Salas et al. 
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2009), and re-exposure to nicotine during withdrawal results in increased activity of MHb and 
IPN neurons (Arvin et al. 2019; Gorlich et al. 2013). Further, injections of antagonists for a4b2* 
or a6b2*, but not a3b4*, nAChRs in the MHb decrease the expression of anxiety-related 
behavior under conditions of nicotine withdrawal in mice (Pang et al. 2016).  Together, these 
findings suggest that nAChRs are involved in various aspects of nicotine withdrawal based on 
their localization and expression patterns within the brain.  
 
Modulators of nAChRs influencing expression and function 
The expression and function of nAChRs may be modulated at various points from protein 
translation to membrane insertion to subsequent function. Early receptor binding studies in 
humans found increased expression of nAChRs in chronic smokers (Benwell et al. 1988; Perry et 
al. 1999), suggesting a change in cellular activation following prolonged nicotine exposure. Given 
that chronic agonist receptor activation typically results in receptor downregulation, this finding 
was unexpected, although it was also evidenced in more controlled rodent studies (Marks et al. 
1983; Marks et al. 1992). The likely mechanism underlying receptor upregulation was recently 
elucidated as it was found that nicotine and nAChR ligands can act as ‘chaperones’ for a4 and b2 
nAChR subunits (Henderson et al. 2014; Kuryatov et al. 2005; Srinivasan et al. 2011), thereby 
allowing for increased expression of the high affinity nAChR subtype in the membrane. As the 
nAChR subunit protein is translated in the endoplasmic reticulum, the chaperone mechanism is 
thought to facilitate transport by promoting the trafficking of the protein to the plasma 
membrane, and subsequent insertion of the assembled nAChR.  
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Intracellular proteins have also been shown to stabilize nAChR subunits in the endoplasmic 
reticulum and regulate subunit assembly into specific nAChR subtypes, resulting in either an 
increase or decrease in nAChR subtype-specific membrane expression (Dau et al. 2013; 
Wanamaker and Green 2007). For instance, a7 nAChRs are selectively targeted to the dendritic 
membrane by Ric-3, thus facilitating receptor expression (Alexander et al. 2010). In contrast, 
members of the Ly-6/neurotoxin gene superfamily, which includes lynx1 and lynx2, have been 
demonstrated to decrease receptor expression by acting as inhibitory chaperones during protein 
translation and trafficking, and moreover, lynx proteins also bind directly to the extracellular face 
of nAChRs on the cell membrane, resulting in a decrease in ligand binding efficiency and increase 
in the desensitization rate for nAChRs containing the a4, a3, a5, a7, b2, and/or b4 subunits 
(George et al. 2017; Ibanez-Tallon et al. 2002; Lyukmanova et al. 2011; Miwa et al. 1999; Nichols 
et al. 2014).  In the cortex, Lynx1 is expressed in both glutamatergic and GABAergic neurons, 
whereas Lynx2 has been mainly localized in glutamatergic neurons (Demars and Morishita 2014). 
Lynx1 also appears to exhibit preferential binding affinity to the α:α interface, which would allow 
for increased interaction with the stoichiometry present in the lower sensitivity α43β22 nAChRs 
(Nichols et al. 2014). In addition to intracellular proteins, other endogenous factors may interact 
with nAChRs to modulate function. For instance, estradiol has been shown to bind to the C-
terminal tail of the a4 subunit to potentiate the activation of a4* nAChRs in the presence of 
acetylcholine, an effect that was selective for a4 as differences were not found with the a3 
subunit (Curtis et al. 2002). More recently, phosphorylation sites have been identified on a4b2* 
nAChRs, suggesting a direct role for the receptor in mediating calcium/calmodulin-dependent 
protein kinase II and protein kinase A intracellular signaling (Miller et al. 2018). Together, these 
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nAChR subtype specific interactions, along with cell type-specific expression patterns, may allow 
for selective modulation of various aspects of cholinergic signaling, thereby permitting each 
endogenous modulator to differentially regulate neural processes. 
 
Beyond nicotine dependence 
Although heavily involved in processes of nicotine dependence, nAChRs have also been 
implicated as mechanisms underlying other disease states, including Alzheimer’s Disease (AD; 
(Lombardo and Maskos 2015)), schizophrenia (specifically, α7; (Jones 2018)), Parkinson’s Disease 
(PD; (Jurado-Coronel et al. 2016)), overeating/weight gain (Shariff et al. 2016), among others. 
Discovery of these mechanisms has led to multiple Phase II clinical trials for nAChR compounds 
that have pro-cognitive effects (although many of these attempts have failed, see (Lewis et al. 
2017)). Varenicline, a full agonist at α7 and a partial agonist at α4β2 nAChRs, is prescribed as a 
smoking cessation agent but also has efficacy in decreasing sucrose consumption and producing 
pro-cognitive effect in rodent models (Potasiewicz et al. 2018; Shariff et al. 2016). Interestingly, 
varenicline may improve cognitive function in patients with schizophrenia (Shim et al. 2012). In 
AD, medications have been developed that inhibit breakdown of the enzymes that metabolize 
acetylcholine (inhibition of acetycholinesterase and/or butyrylcholinesterase), such as Donezepil 
(Aricept) or Rivastigmine (Exelon). Additionally, drug development efforts have included 
compounds that act as positive allosteric modulators at α7 nAChRs in addition to AChE inhibition, 
including Galantamine (Reminyl). Galantamine slows progression of plaque formation 
preclinically (Bhattacharya et al. 2014), and has shown efficacy in improving cognition and global 
functioning in patients with AD (Deardorff et al. 2015). Although statistically significant, these 
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benefits are modest and thus additional drugs are needed. Taken together, these studies 
illustrate a need for refinement of medications that target nAChRs for indications beyond 
nicotine dependence. 
 
Conclusions  
Since the mid-1990’s, significant advances have been made with transgenic animal models to 
allow for better interrogation of specific nAChRs and circuits underlying nicotine dependence. 
Studies have built upon prior findings to reveal integral roles for various subunits in the 
mechanisms underlying nicotine’s actions in the brain, with relevance to addiction. The a4a6b2* 
nAChRs in the mesolimbic pathway appear to be important in mediating the reinforcing 
properties of nicotine, whereas the a5 and b4 nAChR subunits in the MHb-IPN mitigate the 
aversive properties of higher nicotine doses that thereby limit drug intake. In addition to these 
effects on drug consumption, nAChRs have also been implicated in other aspects of the 
dependence processes, including withdrawal, cue-associated learning, and psychiatric 
comorbidity. This foundation holds the promise to provide the field with a basis for new 
discoveries to formulate more efficacious therapeutics. For instance, in consideration of the 
involvement of the a4b2* nAChRs in nicotine reinforcement, it is perhaps not surprising that 
varenicline has similar or greater effectiveness in promoting smoking cessation compared to 
nicotine replacement therapy and other approved therapeutics, such as bupropion (Gonzales et 
al. 2006). Drug development efforts are also focused on modulating the MHb-IPN circuit to 
enhance nicotine-mediated aversion and thus decrease further drug intake (Fowler and Kenny 
2014; Jin et al. 2014). For instance, GLP-1 receptors have been shown to alter nicotine intake via 
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modulation of the MHb-IPN circuit (Tuesta et al. 2017), and a GLP-1 receptor agonist, liraglutide, 
is currently being tested for smoking cessation in a clinical trial (Ashare 2019). In another 
approach to minimize nicotine entry into the brain, NicA2-J1 has been developed as a 
reengineered nicotine-degrading enzyme (Kallupi et al. 2018). Interestingly, while NicA2-J1 does 
not appear to induce significant differences in nicotine intake, decreased withdrawal and relapse-
related behaviors were found in rats (Kallupi et al. 2018). Therefore, the field will certainly 
continue to advance by better defining the various genetic, behavioral and biological mechanisms 
underlying addiction so that long-term abstinence can be readily achieved by those seeking to 
quit tobacco and e-cigarettes. 
 23 
REFERENCES 
Ables JL et al. (2017) Retrograde inhibition by a specific subset of interpeduncular alpha5 
nicotinic neurons regulates nicotine preference Proceedings of the National Academy of 
Sciences of the United States of America 114:13012-13017. 
doi:10.1073/pnas.1717506114 
Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009) Mammalian nicotinic acetylcholine 
receptors: from structure to function Physiol Rev 89:73-120. 
doi:10.1152/physrev.00015.2008 
Alexander JK, Sagher D, Krivoshein AV, Criado M, Jefford G, Green WN (2010) Ric-3 promotes 
alpha7 nicotinic receptor assembly and trafficking through the ER subcompartment of 
dendrites The Journal of neuroscience : the official journal of the Society for 
Neuroscience 30:10112-10126. doi:10.1523/JNEUROSCI.6344-09.2010 
Arvin MC et al. (2019) Chronic nicotine exposure alters the neurophysiology of habenulo-
interpeduncular circuitry The Journal of neuroscience : the official journal of the Society 
for Neuroscience, in press. doi:10.1523/JNEUROSCI.2816-18.2019 
Ashare R (2019) Daily Liraglutide for Nicotine Dependence, NCT03712098. 
https://ClinicalTrials.gov/show/NCT03712098.  
Bellavia A, Wolk A, Orsini N (2016) Differences in age at death according to smoking and age at 
menopause Menopause 23:108-110. doi:10.1097/GME.0000000000000501 
Benwell ME, Balfour DJ, Anderson JM (1988) Evidence that tobacco smoking increases the 
density of (-)-[3H]nicotine binding sites in human brain Journal of neurochemistry 
50:1243-1247 
Berry JN, Engle SE, McIntosh JM, Drenan RM (2015) alpha6-Containing nicotinic acetylcholine 
receptors in midbrain dopamine neurons are poised to govern dopamine-mediated 
behaviors and synaptic plasticity Neuroscience 304:161-175. 
doi:10.1016/j.neuroscience.2015.07.052 
Besson M et al. (2012) Alpha7-nicotinic receptors modulate nicotine-induced reinforcement 
and extracellular dopamine outflow in the mesolimbic system in mice 
Psychopharmacology 220:1-14. doi:10.1007/s00213-011-2422-1 
Bhattacharya S, Haertel C, Maelicke A, Montag D (2014) Galantamine slows down plaque 
formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease PloS 
one 9:e89454. doi:10.1371/journal.pone.0089454 
Bierut LJ et al. (2008) Variants in nicotinic receptors and risk for nicotine dependence The 
American journal of psychiatry 165:1163-1171 
Bohler S, Gay S, Bertrand S, Corringer PJ, Edelstein SJ, Changeux JP, Bertrand D (2001) 
Desensitization of neuronal nicotinic acetylcholine receptors conferred by N-terminal 
segments of the beta 2 subunit Biochemistry 40:2066-2074 
Boulter J, Connolly J, Deneris E, Goldman D, Heinemann S, Patrick J (1987) Functional 
expression of two neuronal nicotinic acetylcholine receptors from cDNA clones 
identifies a gene family Proceedings of the National Academy of Sciences of the United 
States of America 84:7763-7767 
Brody AL et al. (2006) Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine 
receptors Archives of general psychiatry 63:907-915. doi:63/8/907 [pii] 
10.1001/archpsyc.63.8.907 
 24 
Broide RS, Leslie FM (1999) The alpha7 nicotinic acetylcholine receptor in neuronal plasticity 
Mol Neurobiol 20:1-16. doi:10.1007/BF02741361 
Changeux JP et al. (1998) Brain nicotinic receptors: structure and regulation, role in learning 
and reinforcement Brain research Brain research reviews 26:198-216 
Charpantier E, Barneoud P, Moser P, Besnard F, Sgard F (1998) Nicotinic acetylcholine subunit 
mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral 
tegmental area Neuroreport 9:3097-3101 
Chen X et al. (2009) Variants in nicotinic acetylcholine receptors alpha5 and alpha3 increase 
risks to nicotine dependence American journal of medical genetics Part B, 
Neuropsychiatric genetics : the official publication of the International Society of 
Psychiatric Genetics 150B:926-933. doi:10.1002/ajmg.b.30919 
Chini B, Clementi F, Hukovic N, Sher E (1992) Neuronal-type alpha-bungarotoxin receptors and 
the alpha 5-nicotinic receptor subunit gene are expressed in neuronal and nonneuronal 
human cell lines Proceedings of the National Academy of Sciences of the United States 
of America 89:1572-1576. doi:10.1073/pnas.89.5.1572 
Christensen MH, Kohlmeier KA (2016) Age-related changes in functional postsynaptic nicotinic 
acetylcholine receptor subunits in neurons of the laterodorsal tegmental nucleus, a 
nucleus important in drug addiction Addict Biol 21:267-281. doi:10.1111/adb.12194 
Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A (1985) Nicotinic binding in rat brain: 
autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-
bungarotoxin The Journal of neuroscience : the official journal of the Society for 
Neuroscience 5:1307-1315 
Colombo SF, Mazzo F, Pistillo F, Gotti C (2013) Biogenesis, trafficking and up-regulation of 
nicotinic ACh receptors Biochem Pharmacol 86:1063-1073. 
doi:10.1016/j.bcp.2013.06.023 
Corrigall WA, Coen KM (1989) Nicotine maintains robust self-administration in rats on a limited-
access schedule Psychopharmacology 99:473-478 
Couturier S et al. (1990) A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is 
developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX 
Neuron 5:847-856 
Curtis L, Buisson B, Bertrand S, Bertrand D (2002) Potentiation of human alpha4beta2 neuronal 
nicotinic acetylcholine receptor by estradiol Molecular pharmacology 61:127-135 
Dau A, Komal P, Truong M, Morris G, Evans G, Nashmi R (2013) RIC-3 differentially modulates 
alpha4beta2 and alpha7 nicotinic receptor assembly, expression, and nicotine-induced 
receptor upregulation BMC neuroscience 14:47. doi:10.1186/1471-2202-14-47 
Davis JA, Gould TJ (2007) beta2 subunit-containing nicotinic receptors mediate the enhancing 
effect of nicotine on trace cued fear conditioning in C57BL/6 mice Psychopharmacology 
190:343-352. doi:10.1007/s00213-006-0624-8 
Deardorff WJ, Feen E, Grossberg GT (2015) The Use of Cholinesterase Inhibitors Across All 
Stages of Alzheimer's Disease Drugs & aging 32:537-547. doi:10.1007/s40266-015-0273-
x 
Demars MP, Morishita H (2014) Cortical parvalbumin and somatostatin GABA neurons express 
distinct endogenous modulators of nicotinic acetylcholine receptors Mol Brain 7:75. 
doi:10.1186/s13041-014-0075-9 
 25 
Drisdel RC, Green WN (2000) Neuronal alpha-bungarotoxin receptors are alpha7 subunit 
homomers The Journal of neuroscience : the official journal of the Society for 
Neuroscience 20:133-139 
Durand-de Cuttoli R et al. (2018) Manipulating midbrain dopamine neurons and reward-related 
behaviors with light-controllable nicotinic acetylcholine receptors Elife 7. 
doi:10.7554/eLife.37487 
Exley R et al. (2011) Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 
and subunit alpha6 to the reinforcing effects of nicotine Proceedings of the National 
Academy of Sciences of the United States of America 108:7577-7582. doi:1103000108 
[pii] 10.1073/pnas.1103000108 
Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG, Fine A (2001) 
Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat 
hippocampus The Journal of neuroscience : the official journal of the Society for 
Neuroscience 21:7993-8003 
Fenster CP, Hicks JH, Beckman ML, Covernton PJ, Quick MW, Lester RA (1999a) Desensitization 
of nicotinic receptors in the central nervous system Annals of the New York Academy of 
Sciences 868:620-623 
Fenster CP, Rains MF, Noerager B, Quick MW, Lester RA (1997) Influence of subunit 
composition on desensitization of neuronal acetylcholine receptors at low 
concentrations of nicotine The Journal of neuroscience : the official journal of the 
Society for Neuroscience 17:5747-5759 
Fenster CP, Whitworth TL, Sheffield EB, Quick MW, Lester RA (1999b) Upregulation of surface 
alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic 
exposure to nicotine The Journal of neuroscience : the official journal of the Society for 
Neuroscience 19:4804-4814 
Forget B et al. (2018) A Human Polymorphism in CHRNA5 Is Linked to Relapse to Nicotine 
Seeking in Transgenic Rats Current biology : CB 28:3244-3253 e3247. 
doi:10.1016/j.cub.2018.08.044 
Fowler CD et al. (2017) Basic Science and Public Policy: Informed Regulation for Nicotine and 
Tobacco Products Nicotine & tobacco research : official journal of the Society for 
Research on Nicotine and Tobacco. doi:10.1093/ntr/ntx175 
Fowler CD, Kenny PJ (2014) Nicotine aversion: Neurobiological mechanisms and relevance to 
tobacco dependence vulnerability Neuropharmacology 76 Pt B:533-544. 
doi:10.1016/j.neuropharm.2013.09.008 
Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ (2011) Habenular alpha5 nicotinic receptor 
subunit signalling controls nicotine intake Nature 471:597-601 
Fowler CD, Tuesta L, Kenny PJ (2013) Role of alpha5* nicotinic acetylcholine receptors in the 
effects of acute and chronic nicotine treatment on brain reward function in mice 
Psychopharmacology:in press 
Frahm S et al. (2011) Aversion to nicotine is regulated by the balanced activity of beta4 and 
alpha5 nicotinic receptor subunits in the medial habenula Neuron 70:522-535. 
doi:10.1016/j.neuron.2011.04.013 
 26 
Gaimarri A, Moretti M, Riganti L, Zanardi A, Clementi F, Gotti C (2007) Regulation of neuronal 
nicotinic receptor traffic and expression Brain research reviews 55:134-143. 
doi:10.1016/j.brainresrev.2007.02.005 
Gao F et al. (2005) Agonist-mediated conformational changes in acetylcholine-binding protein 
revealed by simulation and intrinsic tryptophan fluorescence J Biol Chem 280:8443-
8451. doi:10.1074/jbc.M412389200 
Gentry CL, Lukas RJ (2002) Regulation of nicotinic acetylcholine receptor numbers and function 
by chronic nicotine exposure Curr Drug Targets CNS Neurol Disord 1:359-385 
George AA, Bloy A, Miwa JM, Lindstrom JM, Lukas RJ, Whiteaker P (2017) Isoform-specific 
mechanisms of alpha3beta4*-nicotinic acetylcholine receptor modulation by the 
prototoxin lynx1 FASEB J 31:1398-1420. doi:10.1096/fj.201600733R 
George AA, Lucero LM, Damaj MI, Lukas RJ, Chen X, Whiteaker P (2012) Function of human 
alpha3beta4alpha5 nicotinic acetylcholine receptors is reduced by the alpha5(D398N) 
variant J Biol Chem 287:25151-25162. doi:10.1074/jbc.M112.379339 
Giniatullin R, Nistri A, Yakel JL (2005) Desensitization of nicotinic ACh receptors: shaping 
cholinergic signaling Trends in neurosciences 28:371-378. 
doi:10.1016/j.tins.2005.04.009 
Ginzkey C, Friehs G, Koehler C, Hackenberg S, Hagen R, Kleinsasser NH (2013) Assessment of 
nicotine-induced DNA damage in a genotoxicological test battery Mutat Res 751:34-39. 
doi:10.1016/j.mrgentox.2012.11.004 
Ginzkey C et al. (2012) Analysis of nicotine-induced DNA damage in cells of the human 
respiratory tract Toxicology letters 208:23-29. doi:10.1016/j.toxlet.2011.09.029 
Girod R, Role LW (2001) Long-lasting enhancement of glutamatergic synaptic transmission by 
acetylcholine contrasts with response adaptation after exposure to low-level nicotine 
The Journal of neuroscience : the official journal of the Society for Neuroscience 
21:5182-5190. doi:21/14/5182 [pii] 
Gonzales D et al. (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial 
agonist, vs sustained-release bupropion and placebo for smoking cessation: a 
randomized controlled trial JAMA : the journal of the American Medical Association 
296:47-55 
Gorlich A, Antolin-Fontes B, Ables JL, Frahm S, Slimak MA, Dougherty JD, Ibanez-Tallon I (2013) 
Reexposure to nicotine during withdrawal increases the pacemaking activity of 
cholinergic habenular neurons Proceedings of the National Academy of Sciences of the 
United States of America 110:17077-17082 
Gotti C, Zoli M, Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and 
their relevance Trends Pharmacol Sci 27:482-491. doi:S0165-6147(06)00175-1 [pii] 
10.1016/j.tips.2006.07.004 
Grabus SD, Martin BR, Imad Damaj M (2005) Nicotine physical dependence in the mouse: 
involvement of the alpha7 nicotinic receptor subtype European journal of pharmacology 
515:90-93 
Graham AJ et al. (2003) Differential nicotinic acetylcholine receptor subunit expression in the 
human hippocampus J Chem Neuroanat 25:97-113 
Hajek P et al. (2019) A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy N 
Engl J Med 380:629-637. doi:10.1056/NEJMoa1808779 
 27 
Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, Bourne Y (2005) Structures of 
Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive 
binding interfaces and conformations EMBO J 24:3635-3646. 
doi:10.1038/sj.emboj.7600828 
Harrison AA, Gasparini F, Markou A (2002) Nicotine potentiation of brain stimulation reward 
reversed by DHbE and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats 
Psychopharmacology 160:56-66 
Harvey SC, Maddox FN, Luetje CW (1996) Multiple determinants of dihydro-beta-erythroidine 
sensitivity on rat neuronal nicotinic receptor alpha subunits Journal of neurochemistry 
67:1953-1959 
Hawkins BT, Abbruscato TJ, Egleton RD, Brown RC, Huber JD, Campos CR, Davis TP (2004) 
Nicotine increases in vivo blood-brain barrier permeability and alters cerebral 
microvascular tight junction protein distribution Brain research 1027:48-58. 
doi:10.1016/j.brainres.2004.08.043 
Henderson BJ et al. (2014) Nicotine exploits a COPI-mediated process for chaperone-mediated 
up-regulation of its receptors J Gen Physiol 143:51-66. doi:10.1085/jgp.201311102 
Hendrickson LM, Guildford MJ, Tapper AR (2013) Neuronal nicotinic acetylcholine receptors: 
common molecular substrates of nicotine and alcohol dependence Frontiers in 
psychiatry 4:29. doi:10.3389/fpsyt.2013.00029 
Ibanez-Tallon I, Miwa JM, Wang HL, Adams NC, Crabtree GW, Sine SM, Heintz N (2002) Novel 
modulation of neuronal nicotinic acetylcholine receptors by association with the 
endogenous prototoxin lynx1 Neuron 33:893-903. doi:S0896627302006323 [pii] 
Jackson KJ, Marks MJ, Vann RE, Chen X, Gamage TF, Warner JA, Damaj MI (2010) Role of alpha5 
nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in 
mice The Journal of pharmacology and experimental therapeutics 334:137-146 
Jackson KJ, Martin BR, Changeux JP, Damaj MI (2008) Differential role of nicotinic acetylcholine 
receptor subunits in physical and affective nicotine withdrawal signs The Journal of 
pharmacology and experimental therapeutics 325:302-312 
Jacob T, Clouden N, Hingorani A, Ascher E (2009) The effect of cotinine on telomerase activity in 
human vascular smooth muscle cells J Cardiovasc Surg (Torino) 50:345-349 
Jain A, Kuryatov A, Wang J, Kamenecka TM, Lindstrom J (2016) Unorthodox Acetylcholine 
Binding Sites Formed by alpha5 and beta3 Accessory Subunits in alpha4beta2* Nicotinic 
Acetylcholine Receptors J Biol Chem 291:23452-23463. doi:10.1074/jbc.M116.749150 
Jensen JJ, Winzer-Serhan UH, Leslie FM (1997) Glial regulation of alpha 7-type nicotinic 
acetylcholine receptor expression in cultured rat cortical neurons Journal of 
neurochemistry 68:112-120 
Jia Y et al. (2016) Nicotine Inhibits Cisplatin-Induced Apoptosis via Regulating alpha5-
nAChR/AKT Signaling in Human Gastric Cancer Cells PloS one 11:e0149120. 
doi:10.1371/journal.pone.0149120 
Jin X, Bermudez I, Steinbach JH (2014) The nicotinic alpha5 subunit can replace either an 
acetylcholine-binding or nonbinding subunit in the alpha4beta2* neuronal nicotinic 
receptor Molecular pharmacology 85:11-17. doi:10.1124/mol.113.089979 
 28 
Jones C (2018) alpha7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive 
Decline in Schizophrenia Journal of clinical psychopharmacology 38:247-249. 
doi:10.1097/JCP.0000000000000859 
Jurado-Coronel JC, Avila-Rodriguez M, Capani F, Gonzalez J, Moran VE, Barreto GE (2016) 
Targeting the Nicotinic Acetylcholine Receptors (nAChRs) in Astrocytes as a Potential 
Therapeutic Target in Parkinson's Disease Current pharmaceutical design 22:1305-1311 
Kaiser S, Wonnacott S (2000) alpha-bungarotoxin-sensitive nicotinic receptors indirectly 
modulate [(3)H]dopamine release in rat striatal slices via glutamate release Molecular 
pharmacology 58:312-318 
Kallupi M, Xue S, Zhou B, Janda KD, George O (2018) An enzymatic approach reverses nicotine 
dependence, decreases compulsive-like intake, and prevents relapse Sci Adv 
4:eaat4751. doi:10.1126/sciadv.aat4751 
Kaneda K (2017) The contribution of neuroplasticity induced in cholinergic neurons of the 
laterodorsal tegmental nucleus to cocaine addiction Nihon shinkei seishin yakurigaku 
zasshi = Japanese journal of psychopharmacology 37:1-7 
Kaneda K, Kamii H, Taoka N, Minami M (2016) The role of neuroplasticity in cholinergic neurons 
of the laterodorsal tegmental nucleus for cocaine addiction Nihon Arukoru Yakubutsu 
Igakkai zasshi = Japanese journal of alcohol studies & drug dependence 51:259-267 
Kapoor M et al. (2012) Variants located upstream of CHRNB4 on chromosome 15q25.1 are 
associated with age at onset of daily smoking and habitual smoking PloS one 7:e33513 
Karlin A (2002) Emerging structure of the nicotinic acetylcholine receptors Nat Rev Neurosci 
3:102-114 
Kenny PJ, Markou A (2005) Conditioned nicotine withdrawal profoundly decreases the activity 
of brain reward systems The Journal of neuroscience : the official journal of the Society 
for Neuroscience 25:6208-6212. doi:25/26/6208 [pii] 10.1523/JNEUROSCI.4785-04.2005 
Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP (2001) Molecular and physiological 
diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei The 
Journal of neuroscience : the official journal of the Society for Neuroscience 21:1452-
1463 
Kuryatov A, Luo J, Cooper J, Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to 
up-regulate human alpha4beta2 acetylcholine receptors Molecular pharmacology 
68:1839-1851. doi:10.1124/mol.105.012419 
Lallai V et al. (2019) Nicotine Acts on Cholinergic Signaling Mechanisms to Directly Modulate 
Choroid Plexus Function eNeuro 6. doi:10.1523/ENEURO.0051-19.2019 
Lee HW et al. (2018) E-cigarette smoke damages DNA and reduces repair activity in mouse lung, 
heart, and bladder as well as in human lung and bladder cells Proceedings of the 
National Academy of Sciences of the United States of America 115:E1560-E1569. 
doi:10.1073/pnas.1718185115 
Lewis AS, van Schalkwyk GI, Bloch MH (2017) Alpha-7 nicotinic agonists for cognitive deficits in 
neuropsychiatric disorders: A translational meta-analysis of rodent and human studies 
Progress in neuro-psychopharmacology & biological psychiatry 75:45-53. 
doi:10.1016/j.pnpbp.2017.01.001 
 29 
Lombardo S, Maskos U (2015) Role of the nicotinic acetylcholine receptor in Alzheimer's disease 
pathology and treatment Neuropharmacology 96:255-262. 
doi:10.1016/j.neuropharm.2014.11.018 
Lotfipour S et al. (2013) Targeted deletion of the mouse alpha2 nicotinic acetylcholine receptor 
subunit gene (Chrna2) potentiates nicotine-modulated behaviors The Journal of 
neuroscience : the official journal of the Society for Neuroscience 33:7728-7741 
Lotfipour S et al. (2017) alpha2* Nicotinic acetylcholine receptors influence hippocampus-
dependent learning and memory in adolescent mice Learning & memory 24:231-244. 
doi:10.1101/lm.045369.117 
Lyukmanova EN et al. (2011) NMR structure and action on nicotinic acetylcholine receptors of 
water-soluble domain of human LYNX1 J Biol Chem 286:10618-10627. 
doi:10.1074/jbc.M110.189100 
Ma X et al. (2014) alpha5 Nicotinic acetylcholine receptor mediates nicotine-induced HIF-1alpha 
and VEGF expression in non-small cell lung cancer Toxicology and applied pharmacology 
278:172-179. doi:10.1016/j.taap.2014.04.023 
Mameli-Engvall M, Evrard A, Pons S, Maskos U, Svensson TH, Changeux JP, Faure P (2006) 
Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors Neuron 
50:911-921 
Mansvelder HD, Keath JR, McGehee DS (2002) Synaptic mechanisms underlie nicotine-induced 
excitability of brain reward areas Neuron 33:905-919 
Mansvelder HD, McGehee DS (2002) Cellular and synaptic mechanisms of nicotine addiction J 
Neurobiol 53:606-617. doi:10.1002/neu.10148 
Markou A, Paterson NE (2001) The nicotinic antagonist methyllycaconitine has differential 
effects on nicotine self-administration and nicotine withdrawal in the rat Nicotine & 
tobacco research : official journal of the Society for Research on Nicotine and Tobacco 
3:361-373 
Marks MJ, Burch JB, Collins AC (1983) Effects of chronic nicotine infusion on tolerance 
development and nicotinic receptors The Journal of pharmacology and experimental 
therapeutics 226:817-825 
Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, Collins AC 
(1992) Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine 
treatment The Journal of neuroscience : the official journal of the Society for 
Neuroscience 12:2765-2784 
Maskos U et al. (2005) Nicotine reinforcement and cognition restored by targeted expression of 
nicotinic receptors Nature 436:103-107. doi:nature03694 [pii] 10.1038/nature03694 
McGehee DS, Heath MJ, Gelber S, Devay P, Role LW (1995) Nicotine enhancement of fast 
excitatory synaptic transmission in CNS by presynaptic receptors Science 269:1692-1696 
McGranahan TM, Patzlaff NE, Grady SR, Heinemann SF, Booker TK (2011) Alpha4beta2 Nicotinic 
Acetylcholine Receptors on Dopaminergic Neurons Mediate Nicotine Reward and 
Anxiety Relief The Journal of neuroscience : the official journal of the Society for 
Neuroscience 31:10891-10902. doi:31/30/10891 [pii] 10.1523/JNEUROSCI.0937-11.2011 
Miech R, Johnston L, O'Malley PM, Bachman JG, Patrick ME (2019) Adolescent Vaping and 
Nicotine Use in 2017-2018 - U.S. National Estimates N Engl J Med 380:192-193. 
doi:10.1056/NEJMc1814130 
 30 
Mifsud JC, Hernandez L, Hoebel BG (1989) Nicotine infused into the nucleus accumbens 
increases synaptic dopamine as measured by in vivo microdialysis Brain research 
478:365-367 
Miller MB, Wilson RS, Lam TT, Nairn AC, Picciotto MR (2018) Evaluation of the 
Phosphoproteome of Mouse Alpha 4/Beta 2-Containing Nicotinic Acetylcholine 
Receptors In Vitro and In Vivo Proteomes 6. doi:10.3390/proteomes6040042 
Miller PS, Smart TG (2010) Binding, activation and modulation of Cys-loop receptors Trends 
Pharmacol Sci 31:161-174. doi:10.1016/j.tips.2009.12.005 
Miwa JM, Ibanez-Tallon I, Crabtree GW, Sanchez R, Sali A, Role LW, Heintz N (1999) Lynx1, an 
endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian 
CNS Neuron 23:105-114 
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C (2016) Neuronal Acetylcholine Nicotinic 
Receptors as New Targets for Lung Cancer Treatment Current pharmaceutical design 
22:2160-2169 
Nakada T et al. (2012) Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a 
nicotine metabolite through activation of PI3K/Akt pathway J Toxicol Sci 37:555-563 
Nichols WA, Henderson BJ, Yu C, Parker RL, Richards CI, Lester HA, Miwa JM (2014) Lynx1 shifts 
alpha4beta2 nicotinic receptor subunit stoichiometry by affecting assembly in the 
endoplasmic reticulum J Biol Chem 289:31423-31432. doi:10.1074/jbc.M114.573667 
Nisell M, Nomikos GG, Svensson TH (1994) Systemic nicotine-induced dopamine release in the 
rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area 
Synapse 16:36-44. doi:10.1002/syn.890160105 
Noda M, Kobayashi AI (2017) Nicotine inhibits activation of microglial proton currents via 
interactions with alpha7 acetylcholine receptors J Physiol Sci 67:235-245. 
doi:10.1007/s12576-016-0460-5 
Orejarena MJ, Herrera-Solis A, Pons S, Maskos U, Maldonado R, Robledo P (2012) Selective re-
expression of beta2 nicotinic acetylcholine receptor subunits in the ventral tegmental 
area of the mouse restores intravenous nicotine self-administration 
Neuropharmacology 63:235-241. doi:10.1016/j.neuropharm.2012.03.011 
Pang X, Liu L, Ngolab J, Zhao-Shea R, McIntosh JM, Gardner PD, Tapper AR (2016) Habenula 
cholinergic neurons regulate anxiety during nicotine withdrawal via nicotinic 
acetylcholine receptors Neuropharmacology 107:294-304. 
doi:10.1016/j.neuropharm.2016.03.039 
Papke RL, Porter Papke JK (2002) Comparative pharmacology of rat and human alpha7 nAChR 
conducted with net charge analysis British journal of pharmacology 137:49-61. 
doi:10.1038/sj.bjp.0704833 
Paradiso KG, Steinbach JH (2003) Nicotine is highly effective at producing desensitization of rat 
alpha4beta2 neuronal nicotinic receptors The Journal of physiology 553:857-871. 
doi:10.1113/jphysiol.2003.053447 
Patrick J, Stallcup B (1977) alpha-Bungarotoxin binding and cholinergic receptor function on a 
rat sympathetic nerve line J Biol Chem 252:8629-8633 
Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ (1999) Increased nicotinic receptors in 
brains from smokers: membrane binding and autoradiography studies The Journal of 
pharmacology and experimental therapeutics 289:1545-1552 
 31 
Picciotto MR, Addy NA, Mineur YS, Brunzell DH (2008) It is not "either/or": activation and 
desensitization of nicotinic acetylcholine receptors both contribute to behaviors related 
to nicotine addiction and mood Prog Neurobiol 84:329-342. 
doi:10.1016/j.pneurobio.2007.12.005 
Picciotto MR et al. (1995) Abnormal avoidance learning in mice lacking functional high-affinity 
nicotine receptor in the brain Nature 374:65-67. doi:10.1038/374065a0 
Picciotto MR et al. (1998) Acetylcholine receptors containing the beta2 subunit are involved in 
the reinforcing properties of nicotine Nature 391:173-177. doi:10.1038/34413 
Pons S et al. (2008) Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits 
from ventral tegmental area in systemic nicotine self-administration The Journal of 
neuroscience : the official journal of the Society for Neuroscience 28:12318-12327. 
doi:28/47/12318 [pii] 10.1523/JNEUROSCI.3918-08.2008 
Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996) Effects of nicotine on the nucleus accumbens 
and similarity to those of addictive drugs Nature 382:255-257 
Portugal GS, Kenney JW, Gould TJ (2008) Beta2 subunit containing acetylcholine receptors 
mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning 
Neurobiology of learning and memory 89:106-113. doi:S1074-7427(07)00077-9 [pii] 
10.1016/j.nlm.2007.05.002 
Potasiewicz A, Golebiowska J, Popik P, Nikiforuk A (2018) Procognitive effects of varenicline in 
the animal model of schizophrenia depend on alpha4beta2- and alpha 7-nicotinic 
acetylcholine receptors Journal of psychopharmacology:269881118812097. 
doi:10.1177/0269881118812097 
Quick MW, Lester RA (2002) Desensitization of neuronal nicotinic receptors J Neurobiol 53:457-
478. doi:10.1002/neu.10109 
Ramirez-Latorre J, Yu CR, Qu X, Perin F, Karlin A, Role L (1996) Functional contributions of 
alpha5 subunit to neuronal acetylcholine receptor channels Nature 380:347-351 
Rennie LJ, Bazillier-Bruneau C, Rouesse J (2016) Harm Reduction or Harm Introduction? 
Prevalence and Correlates of E-Cigarette Use Among French Adolescents J Adolesc 
Health 58:440-445. doi:10.1016/j.jadohealth.2015.12.013 
Reuben M, Boye S, Clarke PB (2000) Nicotinic receptors modulating somatodendritic and 
terminal dopamine release differ pharmacologically European journal of pharmacology 
393:39-49 
Rice ME, Cragg SJ (2004) Nicotine amplifies reward-related dopamine signals in striatum Nat 
Neurosci 7:583-584 
Saccone NL et al. (2009) Multiple distinct risk loci for nicotine dependence identified by dense 
coverage of the complete family of nicotinic receptor subunit (CHRN) genes American 
journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of 
the International Society of Psychiatric Genetics 150B:453-466 
Saccone SF et al. (2007) Cholinergic nicotinic receptor genes implicated in a nicotine 
dependence association study targeting 348 candidate genes with 3713 SNPs Human 
molecular genetics 16:36-49 
Salas R, Main A, Gangitano D, De Biasi M (2007) Decreased withdrawal symptoms but normal 
tolerance to nicotine in mice null for the alpha7 nicotinic acetylcholine receptor subunit 
Neuropharmacology 53:863-869 
 32 
Salas R, Pieri F, De Biasi M (2004) Decreased signs of nicotine withdrawal in mice null for the 
beta4 nicotinic acetylcholine receptor subunit The Journal of neuroscience : the official 
journal of the Society for Neuroscience 24:10035-10039 
Salas R, Sturm R, Boulter J, De Biasi M (2009) Nicotinic receptors in the habenulo-
interpeduncular system are necessary for nicotine withdrawal in mice The Journal of 
neuroscience : the official journal of the Society for Neuroscience 29:3014-3018 
Selya AS, Dierker L, Rose JS, Hedeker D, Mermelstein RJ (2018) The Role of Nicotine 
Dependence in E-Cigarettes' Potential for Smoking Reduction Nicotine & tobacco 
research : official journal of the Society for Research on Nicotine and Tobacco 20:1272-
1277. doi:10.1093/ntr/ntx160 
Shariff M et al. (2016) Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar 
Intake PloS one 11:e0150270. doi:10.1371/journal.pone.0150270 
Shen JX, Yakel JL (2012) Functional alpha7 nicotinic ACh receptors on astrocytes in rat 
hippocampal CA1 slices J Mol Neurosci 48:14-21. doi:10.1007/s12031-012-9719-3 
Shim JC et al. (2012) Adjunctive varenicline treatment with antipsychotic medications for 
cognitive impairments in people with schizophrenia: a randomized double-blind 
placebo-controlled trial Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology 37:660-668. doi:10.1038/npp.2011.238 
Shinohara F, Kihara Y, Ide S, Minami M, Kaneda K (2014) Critical role of cholinergic transmission 
from the laterodorsal tegmental nucleus to the ventral tegmental area in cocaine-
induced place preference Neuropharmacology 79:573-579. 
doi:10.1016/j.neuropharm.2014.01.019 
Shoaib M, Gommans J, Morley A, Stolerman IP, Grailhe R, Changeux JP (2002) The role of 
nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste 
aversion Neuropharmacology 42:530-539 
Shytle RD et al. (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic 
receptors Journal of neurochemistry 89:337-343. doi:10.1046/j.1471-4159.2004.02347.x 
Sifat AE, Vaidya B, Kaisar MA, Cucullo L, Abbruscato TJ (2018) Nicotine and electronic cigarette 
(E-Cig) exposure decreases brain glucose utilization in ischemic stroke Journal of 
neurochemistry 147:204-221. doi:10.1111/jnc.14561 
Sine SM et al. (2002) Naturally occurring mutations at the acetylcholine receptor binding site 
independently alter ACh binding and channel gating J Gen Physiol 120:483-496. 
doi:10.1085/jgp.20028568 
Sottile SY, Ling L, Cox BC, Caspary DM (2017) Impact of ageing on postsynaptic neuronal 
nicotinic neurotransmission in auditory thalamus The Journal of physiology 595:5375-
5385. doi:10.1113/JP274467 
Srinivasan R, Pantoja R, Moss FJ, Mackey ED, Son CD, Miwa J, Lester HA (2011) Nicotine up-
regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent 
chaperoning J Gen Physiol 137:59-79. doi:10.1085/jgp.201010532 
St Helen G, Havel C, Dempsey DA, Jacob P, 3rd, Benowitz NL (2016) Nicotine delivery, retention 
and pharmacokinetics from various electronic cigarettes Addiction 111:535-544. 
doi:10.1111/add.13183 
 33 
Stoker AK, Olivier B, Markou A (2012) Role of alpha7- and beta4-containing nicotinic 
acetylcholine receptors in the affective and somatic aspects of nicotine withdrawal: 
studies in knockout mice Behavior genetics 42:423-436 
Stolerman IP, Jarvis MJ (1995) The scientific case that nicotine is addictive Psychopharmacology 
117:2-10; discussion 14-20 
Strasser AA, Souprountchouk V, Kaufmann A, Blazekovic S, Leone F, Benowitz NL, Schnoll RA 
(2016) Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes 
Tobacco regulatory science 2:352-362. doi:10.18001/TRS.2.4.7 
Sun H, Ma X (2015) alpha5-nAChR modulates nicotine-induced cell migration and invasion in 
A549 lung cancer cells Exp Toxicol Pathol 67:477-482. doi:10.1016/j.etp.2015.07.001 
Taoka N, Kamiizawa R, Wada S, Minami M, Kaneda K (2016) Chronic cocaine exposure induces 
noradrenergic modulation of inhibitory synaptic transmission to cholinergic neurons of 
the laterodorsal tegmental nucleus The European journal of neuroscience 44:3035-
3045. doi:10.1111/ejn.13405 
Tapper AR et al. (2004) Nicotine activation of alpha4* receptors: sufficient for reward, 
tolerance, and sensitization Science 306:1029-1032. doi:306/5698/1029 [pii] 
10.1126/science.1099420 
Tuesta LM et al. (2017) GLP-1 acts on habenular avoidance circuits to control nicotine intake 
Nat Neurosci 20:708-716. doi:10.1038/nn.4540 
Villani L, Contestabile A, Niso R (1983) Ultrastructural features and acetylcholinesterase 
histochemistry of the rat habenular complex Acta Anat (Basel) 117:112-120 
Walters CL, Brown S, Changeux JP, Martin B, Damaj MI (2006) The beta2 but not alpha7 subunit 
of the nicotinic acetylcholine receptor is required for nicotine-conditioned place 
preference in mice Psychopharmacology 184:339-344. doi:10.1007/s00213-005-0295-x 
Wanamaker CP, Green WN (2007) Endoplasmic reticulum chaperones stabilize nicotinic 
receptor subunits and regulate receptor assembly J Biol Chem 282:31113-31123. 
doi:10.1074/jbc.M705369200 
Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, Lindstrom J (1996) Assembly of 
human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 
subunits J Biol Chem 271:17656-17665 
Wang JC et al. (2009) Genetic variation in the CHRNA5 gene affects mRNA levels and is 
associated with risk for alcohol dependence Molecular psychiatry 14:501-510 
Wang TW, Gentzke A, Sharapova S, Cullen KA, Ambrose BK, Jamal A (2018) Tobacco Product 
Use Among Middle and High School Students - United States, 2011-2017 MMWR 
Morbidity and mortality weekly report 67:629-633. doi:10.15585/mmwr.mm6722a3 
Wang X, Lippi G, Carlson DM, Berg DK (2013) Activation of alpha7-containing nicotinic receptors 
on astrocytes triggers AMPA receptor recruitment to glutamatergic synapses Journal of 
neurochemistry 127:632-643. doi:10.1111/jnc.12436 
Watkins SS, Epping-Jordan MP, Koob GF, Markou A (1999) Blockade of nicotine self-
administration with nicotinic antagonists in rats Pharmacology, biochemistry, and 
behavior 62:743-751 
Wonnacott S (1997) Presynaptic nicotinic ACh receptors Trends in neurosciences 20:92-98 
 34 
Wonnacott S, Barik J, Dickinson J, Jones IW (2006) Nicotinic receptors modulate transmitter 
cross talk in the CNS: nicotinic modulation of transmitters J Mol Neurosci 30:137-140. 
doi:10.1385/JMN:30:1:137 
Yan Y et al. (2018) Nicotinic Cholinergic Receptors in VTA Glutamate Neurons Modulate 
Excitatory Transmission Cell reports 23:2236-2244. doi:10.1016/j.celrep.2018.04.062 
Yoshikawa H, Hellstrom-Lindahl E, Grill V (2005) Evidence for functional nicotinic receptors on 
pancreatic beta cells Metabolism: clinical and experimental 54:247-254. 
doi:10.1016/j.metabol.2004.08.020 
Zia S, Ndoye A, Nguyen VT, Grando SA (1997) Nicotine enhances expression of the alpha 3, 
alpha 4, alpha 5, and alpha 7 nicotinic receptors modulating calcium metabolism and 
regulating adhesion and motility of respiratory epithelial cells Research communications 
in molecular pathology and pharmacology 97:243-262 
Zoli M, Pistillo F, Gotti C (2015) Diversity of native nicotinic receptor subtypes in mammalian 
brain Neuropharmacology 96:302-311. doi:10.1016/j.neuropharm.2014.11.003 
 
